Skip to content
Calculator
Guide

Peptides for hair loss: what the trials show

Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board

A young man examining hair loss indoors, reflecting self-care concerns
Photo by Sanket Mishra on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • The yardsticks are finasteride and minoxidil, which have large placebo-controlled trials: finasteride 1 mg added about 107 hairs over placebo in a one-inch circle of balding crown in a year, and 5% minoxidil grew 45% more hair than 2% at 48 weeks.
  • Peptide hair ingredients have nothing comparable. Their trials test blends: one in 32 people showed no significant difference from a weaker 3% minoxidil, and a larger one reported in a 2025 review rated a three-blend product above 5% minoxidil without published hair counts. GHK-Cu's hair evidence is case series and mixtures with other actives.
  • PTD-DBM, a research peptide from a Korean laboratory, regrew hair in mice by switching on Wnt signalling, but no human trial is registered. It is a laboratory result, not a treatment.

The baseline: what proven treatments achieve

Any claim about a hair peptide has to be measured against what the standard treatments already do, and those treatments have large, long trials. In two one-year trials of 1,553 men aged 18 to 41 with male-pattern hair loss, run by finasteride's maker Merck, finasteride 1 mg a day by mouth improved scalp hair by every measure. In a one-inch circle of balding crown scalp that started with about 876 hairs, finasteride-treated men had 107 more hairs than the placebo group at one year and 138 more at two, while men on placebo kept losing hair 1. Topical minoxidil has a similar record. In a 48-week trial of 393 men, 5% minoxidil twice daily was clearly better than 2% minoxidil and placebo, producing 45% more regrowth than the 2% solution, with a faster response and more itching and irritation 2.

Those numbers matter for two reasons. They show the size of effect an approved treatment produced in these trials, and they show the kind of trial needed to prove it: hundreds of people, a placebo, a year or more, and hair counts. None of the peptide studies below meets that standard.

What is in a peptide hair serum

Hair serums are sold on a list of named actives, many of them branded ingredient blends. A 2025 review of the most heavily marketed topical hair actives, including Redensyl, Procapil, Capixyl and AnaGain, found that most had been studied in combination with other agents, in trials with small samples, no comparison against standard therapies, mismatched groups, unclear types of hair loss and conflicts of interest 3. The review concluded they might serve as add-ons or for people who cannot tolerate standard treatment, not as replacements 3. That is the frame for everything below: the question is not whether these ingredients do anything, but whether the evidence is good enough to tell.

Capixyl and acetyl tetrapeptide-3

Capixyl, a branded cosmetic ingredient, combines the peptide acetyl tetrapeptide-3 with a red clover extract rich in biochanin A 3. The most direct comparison we found tested a combination of biochanin A, acetyl tetrapeptide-3 and ginseng extracts against 3% minoxidil in 32 men and women with mild to moderate androgenetic alopecia, applied twice daily for 24 weeks in a triple-blind design. Terminal hair counts, read from photographs by an expert panel, rose by 8.3% with the herbal combination and 8.7% with minoxidil, a difference that was not statistically significant; one person on minoxidil developed scalp eczema, and none on the combination had a local reaction 4.

That is a respectable result for a cosmetic ingredient, and it is also easy to over-read. The comparator was 3% minoxidil, weaker than the 5% concentration shown to outperform lower strengths 2; the trial was small enough that a real difference could have been missed; and it tested a mixture, so it cannot say what the peptide contributed on its own. The authors themselves called for larger, longer studies 4.

The same 2025 review reports a larger trial: 106 men with androgenetic alopecia applied either a combination of Redensyl, Capixyl and Procapil or 5% minoxidil twice a day for 24 weeks, and the combination scored higher on the researchers' rating (64.7% against 25.5%), on photographic evaluation (88.9% against 60%) and on self-evaluation 3. The review gives no hair counts for that trial, the blend holds three branded actives (Procapil itself contains the peptide biotinyl-GHK), and we could not find the trial in PubMed to read it directly, so it says nothing about the peptide alone 3.

GHK-Cu and copper peptides

GHK-Cu Medium is a copper tripeptide; GHK, with or without copper, is used in hair and skin care products 5. For hair, the human evidence is thin and tangled with other ingredients. A report from two São Paulo clinics on four patients treated with a fractional laser followed by topical finasteride, several growth factors and 1% copper peptide described improved regrowth in all four 6; with a laser, finasteride and growth factors in the mix, the copper peptide's part cannot be separated. An open-label pilot study by doctors at a Mumbai cosmetic clinic gave 1,000 patients scalp injections of a formulation containing four growth factors, thymosin beta-4 and copper tripeptide-1 every three weeks for eight sessions, and reported a significant reduction in hair fall on the pull test in 83% and a significant rise in hair count at one year; it had no control group 7. A 2026 review of GHK-Cu notes a newer 18-person split-face eyebrow study that reported positive cosmetic hair outcomes but did not establish what form of the peptide was present or how much reached the follicles 8.

Laboratory work supports a plausible mechanism without proving an effect on hair. In cultured human keratinocytes and skin models, copper-free GHK increased markers of stemness and proliferation in basal cells, similar to the copper complex 5. The broader point from the 2026 review applies here too: studies often treat GHK-Cu as a single ingredient although its chemical state varies with the formulation, which makes it hard to know what any study actually tested, and the review calls it promising but unproven 8. Our guide to copper peptides for skin covers the rest of its evidence.

PTD-DBM: a research peptide from the laboratory

PTD-DBM comes from a Korean research group studying a protein called CXXC5, which acts as a brake on the Wnt/beta-catenin pathway that drives hair follicle growth. In a 2017 study, CXXC5 was found raised in shrunken follicles of human balding scalps, mice lacking it regrew hair faster, and a competitor peptide that blocks CXXC5's binding to a partner protein, Dishevelled, activated Wnt signalling and accelerated hair regrowth and the formation of new follicles after wounding in mice 9. A 2023 study by the same group applied the peptide, PTD-DBM, to the skin of mice and found that it reversed hair loss caused by prostaglandin D2; hair loss driven by DHT, the hormone behind male-pattern loss, was tested with KY19382, a small molecule acting on CXXC5 and on GSK-3 beta, not with the peptide 10.

It is a well-built line of research, and it is entirely preclinical. A search of ClinicalTrials.gov on October 27, 2026 found no registered study of PTD-DBM or of KY19382 11. The papers' corresponding author is listed with CK Biotechnology in 2017 9 and in 2023 as chief executive of CK Regeon, which holds a licence to develop the Wnt activator described 10. For PTD-DBM there is no human dose, no human safety data and no evidence that it regrows human hair.

Thymosin beta-4 and growth-factor mixtures

Thymosin beta-4 Medium appears in some injected hair formulations, such as the one in the 1,000-patient Indian study, alongside growth factors and copper tripeptide 7. That study cannot show what any single ingredient did, and it lacked a comparison group; none of the mixture's components was tested on its own 7. Our TB-500 article explains why thymosin beta-4 and the fragment sold as TB-500 are not the same molecule.

How to judge a peptide hair product

Four questions sort the evidence quickly. Was the ingredient tested alone, or only inside a blend? Was there a placebo or a standard treatment as comparator, and if so, which strength? How many people, for how long, and were hairs counted objectively or rated from photographs? And who ran the study? Most peptide hair actives fail at least two of these 3. Against that, finasteride and 5% minoxidil have placebo-controlled trials in hundreds of people over 48 weeks or more 1 2.

None of this means peptide serums are useless. A product that is well tolerated and might add a little to a standard treatment can be a reasonable choice for someone who cannot use minoxidil or finasteride, which is roughly what the 2025 review suggests 3. It does mean that a serum is not a substitute for a proven treatment, and that hair loss with an unclear cause, sudden onset or patchy pattern should be seen by a dermatologist, because it may not be androgenetic at all.

Frequently asked questions

Do peptides help hair growth?

The evidence is weak. A peptide blend (acetyl tetrapeptide-3 with biochanin A and ginseng) showed no significant difference from 3% minoxidil in 32 people over 24 weeks, and a 2025 review reports a three-blend product rated above 5% minoxidil in 106 men without published hair counts. No peptide has been tested alone in trials comparable to finasteride or 5% minoxidil.

Does GHK-Cu regrow hair?

Not proven. Its hair evidence is a four-patient case series combined with other treatments, a single-arm injected mixture and a small eyebrow study, plus laboratory work.

What is PTD-DBM?

A research peptide that blocks the protein CXXC5 and activates Wnt signalling. It regrew hair in mice, but no human trial was registered on ClinicalTrials.gov as of October 27, 2026.

Is Capixyl as good as minoxidil?

In one 32-person trial, a Capixyl-type combination showed no significant difference from 3% minoxidil over 24 weeks, but 5% minoxidil is stronger and the trial was too small to rule out a difference. A 106-man trial reported in a 2025 review rated a blend of Capixyl with two other actives above 5% minoxidil, without published hair counts.

Sources

  1. Kaufman, K. D., et al. (1998). Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol, 39(4 Pt 1), 578-89. PMID: 9777765
  2. Olsen, E. A., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol, 47(3), 377-85. PMID: 12196747
  3. Bikash, C. (2025). Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology, 17(1), 13-19. PMID: 40654553
  4. Lueangarun, S., et al. (2020). An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial. J Clin Aesthet Dermatol, 13(10), 32-37. PMID: 33584955
  5. Choi, H. R., et al. (2012). Stem cell recovering effect of copper-free GHK in skin. J Pept Sci, 18(11), 685-90. PMID: 23019153
  6. Bertin, A. C. J., et al. (2018). Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. J Cosmet Laser Ther, 20(7-8), 391-394. PMID: 29452017
  7. Kapoor, R., et al. (2018). Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther, 20(6), 369-379. PMID: 29482481
  8. Mateescu, D. M., et al. (2026). GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 18(9). PMID: 42797253
  9. Lee, S. H., et al. (2017). Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol, 137(11), 2260-2269. PMID: 28595998
  10. Ryu, Y. C., et al. (2023). CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2). Cells, 12(4). PMID: 36831222
  11. ClinicalTrials.gov search for 'PTD-DBM' and 'KY19382', October 27, 2026: no registered studies. ClinicalTrials.gov

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead